Effects of Rosemary Essential Oil on Human Cognition (Rosmarinus)
28. april 2026 opdateret af: Heloisa de Freitas Pacífico, Federal University of Paraíba
The Use of Rosmarinus Officinalis L. Essential Oil (Camphor and Cineol Chemotypes) in Cognition: a Randomized, Double-blind, Placebo-controlled Study
Aromatherapy is one of the complementary therapies that is carried out through essential oils.
The essential oil of Rosmarinus Officinalis L. (rosemary) has been gaining attention in aromatherapy research, as studies have shown that the use of this oil is one of the promising non-pharmacological therapies for cognition.
In this way, inhalation of rosemary essential oil is one of the forms of cognitive intervention across different age groups.
The study will aim to analyze the effect of rosemary essential oil, with the following chemotypes: camphor and cineole, on the cognitive performance of adults.
Significant differences are expected between the control (placebo) and experimental groups, given that studies in humans have already shown significant effects of rosemary essential oil on cognition.
Considering the inclusion and exclusion criteria of the study, participants will be allocated to either the control or experimental group.
Consequently, the application of the tests will be carried out neuropsychological tests for the pre-test evaluation, followed by aromatherapy (acute phase) and the reapplication of the tests (post-test phase 1).
For 14 days, the participants will chronically use rosemary essential oil and at the end they will participate in the reapplication of the neuropsychological tests (post-test phase 2).
For inferential analyses, the ANOVA test or its non-parametric equivalent will be used.
In addition, linear regressions may be performed to verify how much the essential oil can predict the outcome of the study's dependent variables.
Effect Size will also be calculated.
Keywords: Chronic intervention; neuropsychology; aromatherapy.
Studieoversigt
Status
Aktiv, ikke rekrutterende
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
63
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Paraíba
-
João Pessoa, Paraíba, Brasilien, 58062-106
- Helô
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
Tager imod sunde frivillige
Ja
Beskrivelse
Inclusion Criteria:
- 1a Healthy adults
- 1b should be able to inhale the essential oil
Exclusion Criteria:
- 2a Neurodegenerative diseases
- 2b Traumatic brain injury
- 2c Brain tumors
- 2d Multiple sclerosis
- 2e Epileptic seizures
- 2f Anxiety Disorder
- 2g Depressive Disorders,
- 2h Uncontrolled arterial hypertension,
- 2i nutritional deficiency or thyroid disease.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: essential oil of Rosmarinus officinalis 1
Inhalation of 2 drops of rosemary camphor essential oil for 5 minutes, once a day for 1 week consecutive on a cotton pad followed
|
oil essential
|
|
Ingen indgriben: Placebo
Inhalation of 2 drops of sunflower essential oil for 5 minutes, once a day for 1 week consecutive on a cotton pad followed
|
|
|
Aktiv komparator: essential oil of Rosmarinus officinalis 2
Inhalation of 2 drops of rosemary cineol essential oil for 5 minutes, for once a day for 1 week consecutive on a cotton pad followed
|
oil essential
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
STROOP TEST
Tidsramme: Cognitive tests were administered at the following stages: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
Unit of measurement: time (seconds)
|
Cognitive tests were administered at the following stages: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Subteste Digits of the Test WAIS-III - (Wechsler Adult Scale)
Tidsramme: Cognitive tests were administered at the following stages: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1a. Maximum raw score: 30 1b. Minimum raw score: 2 |
Cognitive tests were administered at the following stages: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Subtest Number and Letter Sequence of the WAIS-III Test - (Wechsler Adult Scale)
Tidsramme: Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1.0 Measurement Units: raw score 1a. Maximum raw score: 21 1b. Minimum raw score: 0 |
Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Tower of London
Tidsramme: Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1.0 Measurement Units: raw score 1a. Maximum raw score: 46 1b. Minimum raw score: 0 |
Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Token Test
Tidsramme: Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1.0 Measurement Units: raw score 1a. Maximum raw score: 36 1b. Minimum raw score: 0 |
Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Corsi Blocks
Tidsramme: Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1.0 Measurement Units: raw score 1a. Maximum raw score: 30 1b. Minimum raw score: 0 |
Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Hopkins Verbal Learning
Tidsramme: Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1.0 Measurement Units: raw score 1a. Maximum raw score: 0 1b. Minimum raw score: 36 |
Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. marts 2025
Primær færdiggørelse (Anslået)
1. december 2026
Studieafslutning (Anslået)
31. december 2026
Datoer for studieregistrering
Først indsendt
13. april 2026
Først indsendt, der opfyldte QC-kriterier
28. april 2026
Først opslået (Faktiske)
1. maj 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
1. maj 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
28. april 2026
Sidst verificeret
1. april 2026
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- 80434324.0.0000.5188
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .